Sutro Biopharma Inc. (STRO) and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) Comparing side by side

As Biotechnology companies, Sutro Biopharma Inc. (NASDAQ:STRO) and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) are our subject to compare. And more specifically their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sutro Biopharma Inc. 11 4.37 N/A -1.66 0.00
ZIOPHARM Oncology Inc. 5 0.00 N/A 0.94 7.37

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Sutro Biopharma Inc. 0.00% 0% 0%
ZIOPHARM Oncology Inc. 0.00% -426.7% 180.2%


Sutro Biopharma Inc.’s Current Ratio is 5.7 while its Quick Ratio is 5.7. On the competitive side is, ZIOPHARM Oncology Inc. which has a 8.9 Current Ratio and a 8.9 Quick Ratio. ZIOPHARM Oncology Inc. is better positioned to pay off short and long-term obligations compared to Sutro Biopharma Inc.

Analyst Recommendations

Recommendations and Ratings for Sutro Biopharma Inc. and ZIOPHARM Oncology Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sutro Biopharma Inc. 0 0 1 3.00
ZIOPHARM Oncology Inc. 0 0 2 3.00

Sutro Biopharma Inc.’s upside potential currently stands at 82.23% and an $16 average target price. Meanwhile, ZIOPHARM Oncology Inc.’s average target price is $7, while its potential upside is 47.06%. Based on the data delivered earlier, Sutro Biopharma Inc. is looking more favorable than ZIOPHARM Oncology Inc., analysts view.

Insider and Institutional Ownership

Sutro Biopharma Inc. and ZIOPHARM Oncology Inc. has shares owned by institutional investors as follows: 73.1% and 45.3%. Insiders owned 21.23% of Sutro Biopharma Inc. shares. On the other hand, insiders owned about 0.5% of ZIOPHARM Oncology Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sutro Biopharma Inc. 1.9% -4.09% 13.27% 5.52% 0% 24.94%
ZIOPHARM Oncology Inc. 21.75% 25.95% 60.28% 230.48% 184.43% 271.12%

For the past year Sutro Biopharma Inc.’s stock price has smaller growth than ZIOPHARM Oncology Inc.


On 5 of the 9 factors ZIOPHARM Oncology Inc. beats Sutro Biopharma Inc.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to IntrexonÂ’s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma (GBM). Its synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells, and T cell receptors. It also has a research and development agreement with the National Cancer Institute utilizing Sleeping Beauty System to generate T cells receptors for the treatment of solid tumors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.